A Phase 1/2 Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults With Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
Latest Information Update: 19 Jul 2024
At a glance
- Drugs Blinatumomab (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Amgen
- 12 Jul 2024 Planned End Date changed from 21 Sep 2028 to 24 Dec 2032.
- 12 Jul 2024 Planned primary completion date changed from 23 Nov 2026 to 25 Jul 2031.
- 01 Apr 2024 Results published in the American Journal of Hematology